Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology (Q38570558)

4 September 2017

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology (English)

1 reference

4 September 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Michael M Page

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

1 September 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

4 September 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1505-1515

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

The role of early LDL lowering to prevent the onset of atherosclerotic disease

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Statins in the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Resistance and intolerance to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Cellular and molecular mechanisms of statins: an update on pleiotropic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Lipoprotein(a) as a therapeutic target in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Latest developments in the treatment of lipoprotein (a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Lipid lowering with PCSK9 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Sorting an LDL receptor with bound PCSK9 to intracellular degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1073712

10.1517/17425255.2015.1073712

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26293511%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference